Aquis Stock Exchange Weekly Highlights 01/03/24

Invinity Energy Systems plc announced that it has entered into an agreement with its Taiwanese strategic partner, Everdura, to undertake domestic manufacturing of its next-generation vanadium flow battery product, code-named "Mistral", to serve the Taiwanese and other markets. Under the Agreement, Everdura will manufacture Mistral VFBs to fulfil orders it intends to secure under the terms of the existing reseller agreement which targets more than 255 MWh of product sales over a three-year period. The Agreement states that Everdura will pay Invinity a royalty fee based on a material percentage of the sale price of any Mistral products sold. Everdura will also utilise Invinity's existing supply chain and purchase cell stacks directly from the Company, which will continue to be manufactured by Invinity at its facilities in the UK and Canada. In addition, further to its December 2023 Year-End Business Update, Invinity's product development team has successfully undertaken initial performance testing of the first operating Mistral prototype. The Company reports that these tests have verified Mistral's fundamental performance targets and operating parameters. Read more…

ProBiotix Health plc announced it has entered into a partnership agreement with SymbioPharm, a German company pioneering in microbiome research and knowledge-based probiotics. The company says SymbioPharm has secured its position as a leading innovator and provider of probiotics, medicinal products and dietary supplements in Germany, Austria and Switzerland where it is considered a top tier consumer brand. SymbioPharm's distribution network spans direct-to-consumer channels as well as a comprehensive online and offline pharmacy presence. The agreement allows SymbioPharm to utilise ProBiotix's CholBiome® CH formulation to target and reduce cholesterol in their branded consumer products. SymbioPharm has introduced the CholBiome® CH formulation as a premium pharmacy supplement solution across targeted regions. The agreement covers sales in Germany, Austria and Switzerland. Read more…

Ananda Developments Plc announced that its wholly owned subsidiary MRX Medical Limited ("MRX") has signed a Drug Supply Agreement ("DSA") with the University of Edinburgh ("UOE") and NHS Lothian, for the provision of MRX1 cannabidiol ("CBD") oil to UOE and NHS Lothian's endometriosis clinical trial, ENDOCAN-1: A Pilot Randomised Controlled Trial of the Efficacy of a Cannabinoid Oral Tincture in the Management of Endometriosis-Associated Pain.

Ananda's CEO, Melissa Sturgess commented: "The drug supply agreement provides the legal framework for the provision of MRX1, our patent pending cannabinoid medicine, to the endometriosis randomised controlled trial. Importantly it also confirms that MRX retains full IP ownership of the medicine." Read more…

EDX Medical Group plc announced that it has completed a subscription fund-raising round that has raised £5.7million, in aggregate, at 12p per share, following the Company's announcement on 4 February of a placing of shares to raise £4.01 million. Funds raised through two issues will be used to support the acceleration of the development of products to help meet global demand from healthcare providers delivering personalised treatments. The company also announced a retail offer via the Winterflood Retail Access Platform ("WRAP") to raise up to £500,000 through the issue of new ordinary shares. Existing shareholders should contact their broker or wealth manager to participate in the WRAP Retail Offer. The Offer is expected to close at 4.30 p.m. on 5 March 2024. Read more…

Good Life Plus Plc announced the appointment of David Craven to the Board as Non-Executive Chairman. The company says David Craven has been a formidable presence in the global gaming sector for a number of years. In his recent role as CEO of Allwyn Entertainment Limited, he played a pivotal role in securing the fourth National Lottery Licence following an extensive and highly competitive bidding process which led to the subsequent buyout and takeover of the incumbent operator Camelot by Allwyn. Read more…

Substrate AI announced that its total revenue has grown by c.181% in 2023 and is expected to surpass €13 million (unaudited data). This growth has exceeded expectations, in a year marked by company acquisitions, strong investment in products and an increase in international presence. Read more…

Aquis Exchange plc announced the launch of conditional order functionality on its UK and EU MTFs, giving clients another way to use Aquis' cost-effective and low-latency venues to achieve their trading objectives. Read more…